These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7893583)

  • 21. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?
    van den Meiracker AH; Man in 't Veld AJ; Admiraal PJ; Ritsema van Eck HJ; Boomsma F; Derkx FH; Schalekamp MA
    J Hypertens; 1992 Aug; 10(8):803-12. PubMed ID: 1325513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers.
    Anderson PJ; Critchley JA; Tomlinson B; Resplandy G
    Br J Clin Pharmacol; 1995 Apr; 39(4):361-8. PubMed ID: 7640141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-dependent inhibition of angiotensin converting enzyme by enalapril in cats.
    Uechi M; Imamoto S; Ishikawa Y
    J Vet Med Sci; 2002 Apr; 64(4):385-7. PubMed ID: 12014588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.
    Duchin KL; Waclawski AP; Tu JI; Manning J; Frantz M; Willard DA
    J Clin Pharmacol; 1991 Jan; 31(1):58-64. PubMed ID: 1646240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function.
    Shionoiri H; Ueda S; Minamisawa K; Minamisawa M; Takasaki I; Sugimoto K; Gotoh E; Ishii M
    J Cardiovasc Pharmacol; 1992 Sep; 20(3):348-57. PubMed ID: 1279278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses.
    Serrano-Rodríguez JM; Gómez-Díez M; Esgueva M; Castejón-Riber C; Mena-Bravo A; Priego-Capote F; Serrano Caballero JM; Muñoz A
    Vet J; 2016 Feb; 208():38-43. PubMed ID: 26639833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers.
    Rousso P; Buclin T; Nussberger J; Brunner-Ferber F; Brunner HR; Biollaz J
    Eur J Clin Pharmacol; 2000 Jan; 55(10):749-54. PubMed ID: 10663454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The practical assessment of compliance with ACE-inhibitor therapy--a novel approach.
    MacFadyen RJ; Struthers AD
    J Cardiovasc Pharmacol; 1997 Jan; 29(1):119-24. PubMed ID: 9007680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with perindopril in normal volunteers.
    Waeber B; Nussberger J; Perret L; Santoni JP; Brunner HR
    Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():35-41. PubMed ID: 2549899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848).
    Gross V; Treher E; Haag K; Neis W; Wiegand U; Schölmerich J
    J Hepatol; 1993 Jan; 17(1):40-7. PubMed ID: 8445218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril.
    Macdonald NJ; Elliott HL; Hughes DM; Reid JL
    Br J Clin Pharmacol; 1993 Sep; 36(3):201-4. PubMed ID: 9114904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and safety of JTP-4819, a novel specific orally active prolyl endopeptidase inhibitor, in healthy male volunteers.
    Umemura K; Kondo K; Ikeda Y; Kobayashi T; Urata Y; Nakashima M
    Br J Clin Pharmacol; 1997 Jun; 43(6):613-8. PubMed ID: 9205821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
    Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
    Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of quinapril on angiotensin converting enzyme and plasma renin activity as well as pharmacokinetic parameters of quinapril and its active metabolite, quinaprilat, after intravenous and oral administration to mature horses.
    Davis JL; Kruger K; LaFevers DH; Barlow BM; Schirmer JM; Breuhaus BA
    Equine Vet J; 2014 Nov; 46(6):729-33. PubMed ID: 24175935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between ACE activity and mean blood pressure in Iranian normotensive subjects after oral administration of a single dose of enalapril.
    Ziai SA; Seyedhosseini D; Taiebi L; Salekmoghadam E; Mahmoudian M
    Acta Physiol Hung; 2000; 87(2):153-9. PubMed ID: 11205963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute and chronic effects of a novel dihydrobenzofuran analogue and enalapril on blood pressure and plasma and tissue angiotensin converting enzyme activity in the sodium deficient normotensive rat.
    Longman SD; Howlett DR
    Arzneimittelforschung; 1988 May; 38(5):678-82. PubMed ID: 2843192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
    MacFadyen RJ; Lees KR; Reid JL
    Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.
    Ohtawa M; Takayama F; Saitoh K; Yoshinaga T; Nakashima M
    Br J Clin Pharmacol; 1993 Mar; 35(3):290-7. PubMed ID: 8471405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.